Future Directions and Unmet Needs in HER2+ Breast Cancer Therapy

As HER2-targeted therapies continue to evolve, clinicians and healthcare systems anticipate new indications that could expand treatment options across both early and metastatic settings. These advancements may influence formulary planning, requiring institutions to evaluate cost, access, and sequencing strategies to ensure timely adoption while maintaining sustainability. Despite progress, unmet needs remain significant. In early breast cancer, strategies are needed to improve outcomes for patients with residual disease and to minimize treatment-related toxicity. In the metastatic setting, challenges include overcoming resistance, optimizing therapy sequencing, and addressing complex patient subgroups such as those with HER2+/HR+ disease. Addressing these gaps will rely on continued clinical innovation, real-world evidence, and multidisciplinary collaboration, ultimately aiming to deliver more effective, personalized, and tolerable HER2-targeted treatment options across the continuum of care.